Medivation’s Dimebon Shines In Alzheimer’s Open-label Extension Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm recently began confirmatory Phase III; expects to file in 2010 for mild-to-moderate Alzheimer’s.